Thus, DPP-IV inhibitors, which can prevent GLP-1 from the proteolytic degradation and enhance glucose-dependent insulin secretion from pancreatic β cells, have been expected to become a novel approach for the treatment of T2DM with a minimal risk of hypoglycemia and weight gain25, 27, 28. Here, DPP4 is linked to type 2 diabetes mellitus.